Neus Ferrer-Miralles

Author PubWeight™ 24.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The N-ras proto-oncogene can suppress the malignant phenotype in the presence or absence of its oncogene. Cancer Res 2002 1.23
2 Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact 2010 1.01
3 The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials 2010 0.90
4 Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem Pharmacol 2002 0.88
5 Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) 2010 0.87
6 A new bisintercalating anthracycline with picomolar DNA binding affinity. J Med Chem 2005 0.86
7 Modular protein engineering in emerging cancer therapies. Curr Pharm Des 2009 0.86
8 Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol 2009 0.84
9 Bacterial cell factories for recombinant protein production; expanding the catalogue. Microb Cell Fact 2013 0.84
10 Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays. Anal Chim Acta 2009 0.83
11 Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials 2010 0.83
12 Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Appl Microbiol Biotechnol 2015 0.81
13 A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631. Eur J Biochem 2003 0.81
14 Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. Biochim Biophys Acta 2002 0.81
15 Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine 2012 0.81
16 Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today 2008 0.81
17 DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Appl Microbiol Biotechnol 2009 0.80
18 Analytical approaches for assessing aggregation of protein biopharmaceuticals. Curr Pharm Biotechnol 2011 0.79
19 Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. Nanomedicine (Lond) 2011 0.79
20 Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. J Biomol Screen 2010 0.78
21 RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine 2012 0.78
22 In vivo architectonic stability of fully de novo designed protein-only nanoparticles. ACS Nano 2014 0.78
23 Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment. FEBS Lett 2003 0.77
24 Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials 2012 0.77
25 Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors. J Mol Recognit 2009 0.76
26 Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication 2016 0.76
27 Analysing the contribution of nucleic acids to the structure and properties of centric heterochromatin. Genetica 2003 0.76
28 Recombinant protein materials for bioengineering and nanomedicine. Nanomedicine (Lond) 2014 0.76
29 A novel bio-functional material based on mammalian cell aggresomes. Appl Microbiol Biotechnol 2015 0.76
30 Engineering tumor cell targeting in nanoscale amyloidal materials. Nanotechnology 2016 0.75
31 Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production. Bioeng Bugs 2009 0.75
32 Improved performance of protein-based recombinant gene therapy vehicles by tuning downstream procedures. Biotechnol Prog 2013 0.75
33 Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells. Biotechnol Prog 2011 0.75
34 Effect of the DnaK chaperone on the conformational quality of JCV VP1 virus-like particles produced in Escherichia coli. Biotechnol Prog 2014 0.75
35 Engineered biological entities for drug delivery and gene therapy protein nanoparticles. Prog Mol Biol Transl Sci 2011 0.75